1. A comparison of the effects of low- and high-dose atorvastatin on lipoprotein metabolism and inflammatory cytokines in type 2 diabetes: Results from the Protection Against Nephropathy in Diabetes with Atorvastatin (PANDA) randomized trial 
Handrean Soran, MSc, MD, FRCP, Yifen Liu, PhD, Safwaan Adam, MRCP, Tarza Siahmansur, PhD, Jan H. Ho, MRCP, Jonathan D. Schofield, BSc, PhD, MRCP, See Kwok, MD, Matthew Gittins, PhD, Michael France, MRCPath, Naveed Younis, MD, FRCP, J.Martin Gibson, MD, PhD, FRCP, Paul N. Durrington, MD, FRCP, FRCPath, FAHA, FMedSci, Martin K. Rutter, MD, FRCP 
Journal of Clinical Lipidology 
Volume 12, Issue 1, Pages (January 2018)
DOI: /j.jacl
Copyright © 2017 National Lipid Association Terms and Conditions

2. Figure 1
Within-group percentage change from baseline for biomarkers in atorvastatin 10 and 80 mg groups. Statistical significance for changes between the 2 groups are indicated by ∗P < .025, ∗∗P < .001 (data are adjusted for baseline level of biomarker, age, sex, MDRD eGFR [modification of diet in renal disease study estimated glomerular filtration rate], total cholesterol, HbA1c, and use of washout period). The P value considered statistically significant was decreased to <.025 to allow for multiple testing. For more details on statistical significance of changes from baseline, please see Tables 3 and 4. apoAI, apolipoprotein AI; apoB, apolipoprotein B100; apoE, apolipoprotein E; CETP, cholesteryl ester transfer protein; Glyc-apoB, glycated apolipoproteinB100; HDL-C, high-density lipoprotein cholesterol; hs-CRP, high-sensitivity C-reactive protein; LCAT, lecithin–cholesterol acyltransferase; LDL-C, low-density lipoprotein cholesterol; Lp-PLA2, lipoprotein-associated phospholipase A2; Non-HDL-C, non-high-density lipoprotein cholesterol; OxLDL, oxidized LDL; PON1, paraoxonase 1 activity; SAA, serum amyloid A; TC, total cholesterol; TG, triglycerides.
Journal of Clinical Lipidology  , 44-55DOI: ( /j.jacl )
Copyright © 2017 National Lipid Association Terms and Conditions